CATX AMEX
Perspective Therapeutics, Inc.
1W: -48.3%
1M: -52.4%
3M: -58.5%
YTD: -57.4%
1Y: -60.2%
3Y: -59.9%
5Y: -80.9%
$1.19
-0.02 (-1.65%)
Weekly Expected Move ±18.3%
$1
$1
$2
$2
$2
Credit Risk of going bust: higher than 66% of companies Debt: 2.8% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.01 (down 99.4%), Perspective Therapeutics, Inc. would be worth roughly what it owes.
Total debt $4.0M against a stock market value of $135.8M.
Distance to default 3.76 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.9M (short-term plus half of long-term), stock volatility 102.4%; Altman Z -0.56. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.01 (down 99.4%), Perspective Therapeutics, Inc. would be worth roughly what it owes.
Total debt $4.0M against a stock market value of $135.8M.
Distance to default 3.76 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $1.9M (short-term plus half of long-term), stock volatility 102.4%; Altman Z -0.56. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
42 relationships42
As Filer
counterparties named
0
As Counterparty
mentioned by others
6
Rel. Types
2021-03-23
Earliest Filing
2026-02-03
Latest Filing
partner: 20
supplier: 7
target: 5
acquirer: 5
customer: 4
investor: 1
Counterparties (Filed by CATX)
42 relationshipsCompanies named in CATX's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Piper Sandler & Co. | PIPR | partner | Underwriter representative for the offering | 2026-02-03 | View |
| JonesTrading Institutional Services LLC | — | partner | Prior sales agent whose agreement was terminated | 2024-08-13 | View |
| Oppenheimer & Co. Inc. | OPY | partner | Prior sales agent whose agreement was terminated | 2024-08-13 | View |
| RBC Capital Markets, LLC | — | partner | Sales agent for the Controlled Equity Offering | 2024-08-13 | View |
| Cantor Fitzgerald & Co. | — | partner | Sales agent for the Controlled Equity Offering | 2024-08-13 | View |
| Isoray Medical, Inc. | — | target | Wholly owned subsidiary of Perspective Therapeutics that sold its Cesium-131 business assets | 2024-04-16 | View |
| GT Medical Technologies, Inc. | — | acquirer | Acquired Isoray Medical's Cesium-131 brachytherapy business assets | 2024-04-16 | View |
| Isoray Medical, Inc. | — | target | Seller in asset purchase agreement | 2024-04-03 | View |
| Perspective Therapeutics, Inc. | CATX | investor | Seller Parent in asset purchase agreement | 2024-04-03 | View |
| GT Medical Technologies, Inc. | — | acquirer | Buyer in asset purchase agreement | 2024-04-03 | View |
| Perspective Therapeutics, Inc. | CATX | partner | Company issuing securities in the offering | 2024-01-22 | View |
| Oppenheimer & Co. Inc. | OPY | partner | Representative of the underwriters | 2024-01-22 | View |
| Lantheus Holdings, Inc. | LNTH | partner | Strategic partner entering into equity investment, co-development options, and license negotiations with Perspective The | 2024-01-11 | View |
| Mayo Clinic | — | partner | Perspective Therapeutics entered into an exclusive license agreement with Mayo Clinic for the PSMA Alpha-PET DoubLET pla | 2024-01-05 | View |
| RIAR JSC | — | partner | Manufacturer of the cesium-131 salt | 2023-12-06 | View |
| Research Institute of Nuclear Materials, Joint-Stock Company | — | partner | Manufacturer of the cesium-131 salt | 2023-12-06 | View |
| Isotope-Regional Alliance, Joint Stock Company | — | target | Seller and exporter of cesium-131 salt | 2023-12-06 | View |
| MedikorPharma-Ural LLC | — | supplier | Supplier of goods produced by SSC RIAR | 2023-12-06 | View |
| IsoRay Medical Inc. | — | acquirer | Buyer of cesium-131 salt for medical source production | 2023-12-06 | View |
| JonesTrading Institutional Services LLC | — | partner | Agent for at-the-market equity program | 2023-11-17 | View |
| Oppenheimer & Co. Inc. | OPY | partner | Agent for at-the-market equity program | 2023-11-17 | View |
| ViewPoint Molecular Targeting, Inc. | — | customer | Borrower in a $6,000,000 promissory note and security agreement | 2022-11-29 | View |
| Isoray, Inc. | — | acquirer | Acquirer in the merger agreement amendment | 2022-10-24 | View |
| Viewpoint Molecular Targeting, Inc. | — | target | Target company in the merger agreement amendment | 2022-10-24 | View |
| Isoray Acquisition Corp. | — | partner | Wholly-owned subsidiary of Isoray, Inc. used to acquire the target | 2022-10-24 | View |
| Isotope - Regional Alliance, Joint-Stock Company | — | supplier | Seller in the contract for medical isotope supply | 2022-04-15 | View |
| IsoRay Medical Inc. | — | customer | Buyer in the contract for medical isotope supply | 2022-04-15 | View |
| Moving Forward International GmbH | — | partner | Designated consignee for the shipment | 2022-04-15 | View |
| IsoRay Medical Inc. | — | partner | US-based company providing funds and receiving Caesium-131 product | 2021-09-15 | View |
| MedikorPharma-Ural LLC | — | partner | Russian company purchasing enriched barium carbonate for product manufacturing | 2021-09-15 | View |
| SSC RIAR OJSC | — | partner | Russian state corporation performing irradiation and chemical treatment of goods | 2021-09-15 | View |
| V/O ISOTOPE JSC | — | partner | Russian entity involved in product delivery logistics | 2021-09-15 | View |
| Isotope - Regional Alliance, Joint-Stock Company | — | supplier | Seller in the agreement | 2021-08-25 | View |
| MedikorPharma-Ural LLC | — | supplier | Sub-supplier of goods determined by the Buyer | 2021-08-25 | View |
| Isoray Medical Inc. | — | customer | Buyer in the agreement | 2021-08-25 | View |
| MedikorPharma-Ural LLC | — | supplier | Shipper of goods under the contract. | 2021-08-03 | View |
| JSC Isotope | — | target | Seller in contract for goods shipment and calibration services. | 2021-08-03 | View |
| Isoray Medical Inc. | — | acquirer | Buyer in contract for goods shipment and calibration services. | 2021-08-03 | View |
| JSC SSC RIAR | — | supplier | Manufacturer of goods under the contract. | 2021-08-03 | View |
| Research Institute of Nuclear Materials, Joint-Stock Company | — | partner | Manufacturer of the isotopic goods supplied under the contract | 2021-03-23 | View |
| Isotope-Regional Alliance, Joint Stock Company | — | supplier | Seller and consignor of isotopes to IsoRay Medical Inc. | 2021-03-23 | View |
| IsoRay Medical Inc. | — | customer | Buyer of medical isotopes under contract with Isotope-Regional Alliance | 2021-03-23 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-23 | Other Events; Exhibits | View | |
| 2026-10-08 | Other Events; Exhibits | View | |
| 2026-10-01 | Other Events; Exhibits | View | |
| 2026-09-14 | Other Events; Exhibits | View | |
| 2026-09-08 | Other Events; Exhibits | View | |
| 2026-08-10 | Earnings Release; Other Events; Exhibits | View | |
| 2026-08-03 | Other Events; Exhibits | View | |
| 2026-07-01 | Other Events; Exhibits | View | |
| 2026-06-01 | Other Events; Exhibits | View | |
| 2026-05-27 | Shareholder Vote | View | |
| 2026-05-22 | Other Events; Exhibits | View | |
| 2026-05-11 | Earnings Release; Other Events; Exhibits | View | |
| 2026-05-04 | Earnings Release; Other Events; Exhibits | View | |
| 2026-04-20 | Other Events; Exhibits | View | |
| 2026-04-01 | Other Events; Exhibits | View | |
| 2026-03-16 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2026-02-03 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2026-02-02 | Results of Operations and Financial Condition; Other Events; Financial Statements and Exhibits | View | |
| 2026-01-14 | Other Events; Financial Statements and Exhibits | View | |
| 2026-01-12 | Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR